Filtered By:
Condition: Headache
Vaccination: Vaccines

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 88 results found since Jan 2013.

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Neuro ‐COVID‐19
AbstractNeuromuscular manifestations of new coronavirus infection (COVID-19) are frequent and include dizziness, headache, myopathy, and olfactory and gustatory disturbances. Patients with acute central nervous system (CNS) disorders, such as delirium, impaired consciousness, stroke, and convulsive seizures, have a high mortality rate. The encephalitis/encephalopathy that causes consciousness disturbance and seizures can be classified into three conditions, including direct infection with the SARS-CoV-2 virus, encephalopathy caused by CNS damage secondary to systemic hypercytokinemia (cytokine storm), and autoimmune-mediat...
Source: Clinical and Experimental Neuroimmunology - September 12, 2021 Category: Neurology Authors: Takayoshi Shimohata Tags: REVIEW ARTICLE Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fulminant reversible cerebral vasoconstriction syndrome in breakthrough COVID 19 infection
We report a case of fulminant reversible cerebrovascular constriction syndrome (RCVS) in a patient with breakthrough COVID 19 infection who was fully vaccinated. A 64 year old lady, fully vaccinated 2 months back, presented with headache, drowsiness, partial seizures, visual impairment and quadriplegia. Her nasopharyngeal swab was tested positive for SARS COV2 on real time PCR assay.
Source: Journal of Stroke and Cerebrovascular Diseases - November 25, 2021 Category: Neurology Authors: Somdattaa Ray, Vikram V Kamath, Arjun Raju P, Rajesh K.N, Shalini N Source Type: research

Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia
CONCLUSIONS: Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs, abdominal pain, dyspnea, or limb pain/swelling beginning 5–30 days post vaccination, platelet count and d-dimer must be measured, and imaging for thrombosis performed. Confirmation of vaccine-induced immune thrombotic thrombocytopenia diagnosis should be ordered (platelet factor 4/polyanion enzyme-linked immunosorbent assay; platelet factor 4–enhanced platelet activation testing) as treatm...
Source: Critical Care Medicine - December 20, 2021 Category: Emergency Medicine Tags: Online Review Article Source Type: research

COVID ‐19 vaccination in patients with rheumatic diseases: Vaccination rates, patient perspectives, and side effects
ConclusionCOVID-19 vaccination is associated with no increased risk of side effects in any particular disease or drug therapy, therefore vaccination should be encouraged in patients with rheumatic disease. In addition, younger age is associated minimally, while mRNA vaccine is associated with increased side effects.
Source: Immunity, Inflammation and Disease - January 31, 2022 Category: Allergy & Immunology Authors: Yan Kiu Li, Michael Pak Kiu Lui, Lip Long Yam, Chi Shing Cheng, Terence Hon Ting Tsang, Wing Sum Kwok, Ho Yin Chung Tags: ORIGINAL ARTICLE Source Type: research

Cerebral venous sinus thrombosis : An overview of causes, diagnostics and treatment
This article presents the most common causes, including a digression on vaccine-induced immune thrombotic thrombocytopenia (VITT) as well as recommendations for clinical, laboratory testing and imaging diagnostics. In addition, relevant complications with particular reference to epileptic seizures within the framework of the disease entity and guideline-based acute treatment and secondary prophylaxis are presented.PMID:35412038 | DOI:10.1007/s00115-022-01283-5
Source: Der Nervenarzt - April 12, 2022 Category: Neurology Authors: Jan Heckelmann Manuel Dafotakis J örg B Schulz Source Type: research

Global Vaccine Inequality Threatens to Unleash the Next COVID-19 Variant
On a warm South African day in mid-November 2021, Dr. Angelique Coetzee examined a 29-year-old man complaining of extreme fatigue and severe headaches. The symptoms seemed more consistent with heat stroke than the sore throat and fever she had noticed in her COVID-19 patients. By day's end, after seeing several similar cases test positive for COVID-19, Dr. Coetzee, chair of the South African Medical Association, became convinced that something was amiss. Within a week, investigators determined that her patients were infected with a new variant possessing multiple mutations (McKeever 2021), B.1.1.529 BA.1, or Omicron.
Source: International Journal of Infectious Diseases - August 17, 2022 Category: Infectious Diseases Authors: Richard L. Oehler, Vivian R. Vega Tags: Perspective Source Type: research

Neurological Effects of Monkeypox Largely Unknown, Review Finds
Much remains unknown about the long-term neurologic effects of monkeypox. In anarticle published today inJAMA Neurology, researchers from the National Institute of Neurological Disorders and Stroke (NINDS) and colleagues described how reports of complications from other orthopoxviruses, such as smallpox, may offer clues about the neurologic consequences of monkeypox.“Although the COVID-19 pandemic is the worst pandemic in a century, the recent past has seen several major pandemics, including Zika, Ebola, dengue, West Nile, and AIDS,” wrote B. Jeanne Billioux, M.D., of NINDS and colleagues. “A common thread to these p...
Source: Psychiatr News - September 20, 2022 Category: Psychiatry Tags: febrile seizures/encephalopathy headache JAMA Neurology monkeypox neurological problems smallpox transverse myelitis Source Type: research

Worldwide vaccine inequality threatens to unleash the next COVID-19 variant
On a warm South African day in mid-November 2021, Dr. Angelique Coetzee examined a 29-year-old man complaining of extreme fatigue and severe headaches. The symptoms seemed more consistent with heat stroke than the sore throat and fever she had noticed in her patients with COVID-19. At the end of the day, after seeing several similar cases test positive for COVID-19, Dr. Coetzee, chair of the South African Medical Association, became convinced that something was amiss. Within a week, investigators determined that her patients were infected with a new variant possessing multiple mutations (McKeever,  2021), B.1.1.529 BA.1 or “Omicron”.
Source: International Journal of Infectious Diseases - August 17, 2022 Category: Infectious Diseases Authors: Richard L. Oehler, Vivian R. Vega Tags: Perspective Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study
Fatal complications have occurred after vaccination with ChAdOx1 nCoV-19, a vaccine against Covid-19. Vaccine-induced immune thrombotic thrombocytopenia (VITT) with severe outcome is characterized by venous thrombosis, predominantly in cerebral veins, thrombocytopenia and anti-PF4/polyanion antibodies. Prolonged headaches and cutaneous hemorrhages, frequently observed after the ChAdOx1 nCoV-19 vaccine, have therefore caused anxiety among vaccinees. We investigated whether these symptoms represent a mild form of VITT, with a potential for aggravation, e.g.
Source: Journal of Stroke and Cerebrovascular Diseases - November 17, 2022 Category: Neurology Authors: Nina Haagenrud Schultz, Arne Vasli Lund S øraas, Ingvild Hausberg Sørvoll, Çigdem Akalin Akkök, Annette Vetlesen, Jagjit Singh Bhamra, Maria Therese Ahlen, Pål Andre Holme, Anne-Hege Aamodt, Karolina Skagen, Thor Håkon Skattør, Mona Skjelland, Mark Source Type: research

Response to Letter to the Editor
We thank the authors for their interest in our article and the thoughtful comments. As they correctly point out, the association between the first vaccination with ChAdOx1 nCov -19 vaccine and the described symptoms in our article does not prove any causality. However, cutaneous hemorrhages and headaches were frequently reported side effects after vaccination with ChAdOx1 nCov-19 in the Norwegian corona study cohort in young and previously healthy subjects. In lack of previous experience, there was a fear that these symptoms may have represented a mild form of VITT.
Source: Journal of Stroke and Cerebrovascular Diseases - January 20, 2023 Category: Neurology Tags: Letter to the Editor Source Type: research